Tomer M. Mark
0000-0001-6996-0497
Publication & Citation Trends
Publications
0 total
CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma
Cited by 0
Semantic Scholar
Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression OA
Cited by 1
Semantic Scholar
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies OA
Cited by 30
Semantic Scholar
CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts OA
Cited by 8
Semantic Scholar
Abstract 3956: MYC inhibition overcomes IMiD resistance in heterogeneous multiple myeloma populations
Cited by 0
Semantic Scholar
Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis OA
Cited by 2
Semantic Scholar
309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations OA
Cited by 0
Semantic Scholar
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm OA
Cited by 2
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(206)
Protein Degradation and Inhibitors
(90)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(44)
Peptidase Inhibition and Analysis
(33)
Cancer Treatment and Pharmacology
(32)
Affiliations
Ithaka Harbors
Ben-Gurion University of the Negev
University of Colorado Hospital
NewYork–Presbyterian Hospital
The University of Texas MD Anderson Cancer Center